vs
安进（AMGN）与NATIONAL HEALTHCARE CORP（NHC）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是NATIONAL HEALTHCARE CORP的25.5倍（$9.9B vs $386.5M）。安进净利率更高（13.5% vs 6.4%，领先7.1%）。安进同比增速更快（8.6% vs 4.6%）。安进自由现金流更多（$961.0M vs $6.4M）。过去两年安进的营收复合增速更高（15.1% vs 14.0%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
HCA Healthcare是1968年成立的美国营利性医疗服务运营商，总部位于田纳西州纳什维尔。截至2020年5月，该公司在全美20个州及英国持有并运营186家医院，还有约2400个医疗服务网点，涵盖手术中心、独立急诊室、紧急护理中心及医师诊所，2024年位列美国财富500强第61位。
AMGN vs NHC — 直观对比
营收规模更大
AMGN
是对方的25.5倍
$386.5M
营收增速更快
AMGN
高出3.9%
4.6%
净利率更高
AMGN
高出7.1%
6.4%
自由现金流更多
AMGN
多$954.6M
$6.4M
两年增速更快
AMGN
近两年复合增速
14.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $386.5M |
| 净利润 | $1.3B | $24.8M |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | 8.6% |
| 净利率 | 13.5% | 6.4% |
| 营收同比 | 8.6% | 4.6% |
| 净利润同比 | 112.6% | 308.6% |
| 每股收益（稀释后） | $2.45 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNNHC
| Q4 25 | $9.9B | $386.5M | ||
| Q3 25 | $9.6B | $382.7M | ||
| Q2 25 | $9.2B | $374.9M | ||
| Q1 25 | $8.1B | $373.7M | ||
| Q4 24 | $9.1B | $369.4M | ||
| Q3 24 | $8.5B | $340.2M | ||
| Q2 24 | $8.4B | $300.7M | ||
| Q1 24 | $7.4B | $297.2M |
净利润AMGNNHC
| Q4 25 | $1.3B | $24.8M | ||
| Q3 25 | $3.2B | $39.2M | ||
| Q2 25 | $1.4B | $23.7M | ||
| Q1 25 | $1.7B | $32.2M | ||
| Q4 24 | $627.0M | $6.1M | ||
| Q3 24 | $2.8B | $42.8M | ||
| Q2 24 | $746.0M | $26.8M | ||
| Q1 24 | $-113.0M | $26.2M |
毛利率AMGNNHC
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNNHC
| Q4 25 | 27.6% | 8.6% | ||
| Q3 25 | 26.4% | 7.9% | ||
| Q2 25 | 28.9% | 9.1% | ||
| Q1 25 | 14.5% | 8.2% | ||
| Q4 24 | 25.4% | 7.8% | ||
| Q3 24 | 24.1% | 6.7% | ||
| Q2 24 | 22.8% | 7.5% | ||
| Q1 24 | 13.3% | 5.3% |
净利率AMGNNHC
| Q4 25 | 13.5% | 6.4% | ||
| Q3 25 | 33.7% | 10.3% | ||
| Q2 25 | 15.6% | 6.3% | ||
| Q1 25 | 21.2% | 8.6% | ||
| Q4 24 | 6.9% | 1.6% | ||
| Q3 24 | 33.3% | 12.6% | ||
| Q2 24 | 8.9% | 8.9% | ||
| Q1 24 | -1.5% | 8.8% |
每股收益（稀释后）AMGNNHC
| Q4 25 | $2.45 | $1.58 | ||
| Q3 25 | $5.93 | $2.50 | ||
| Q2 25 | $2.65 | $1.52 | ||
| Q1 25 | $3.20 | $2.07 | ||
| Q4 24 | $1.17 | $0.38 | ||
| Q3 24 | $5.22 | $2.73 | ||
| Q2 24 | $1.38 | $1.73 | ||
| Q1 24 | $-0.21 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $92.8M |
| 总债务越低越好 | $54.6B | $40.0M |
| 股东权益账面价值 | $8.7B | $1.1B |
| 总资产 | $90.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 6.31× | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资AMGNNHC
| Q4 25 | $9.1B | $92.8M | ||
| Q3 25 | $9.4B | $130.6M | ||
| Q2 25 | $8.0B | $111.0M | ||
| Q1 25 | $8.8B | $90.4M | ||
| Q4 24 | $12.0B | $76.1M | ||
| Q3 24 | $9.0B | $84.8M | ||
| Q2 24 | $9.3B | $136.2M | ||
| Q1 24 | $9.7B | $94.0M |
总债务AMGNNHC
| Q4 25 | $54.6B | $40.0M | ||
| Q3 25 | $54.6B | $73.1M | ||
| Q2 25 | $56.2B | $110.0M | ||
| Q1 25 | $57.4B | $134.0M | ||
| Q4 24 | $60.1B | $137.0M | ||
| Q3 24 | $60.4B | $147.0M | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNNHC
| Q4 25 | $8.7B | $1.1B | ||
| Q3 25 | $9.6B | $1.1B | ||
| Q2 25 | $7.4B | $1.0B | ||
| Q1 25 | $6.2B | $1.0B | ||
| Q4 24 | $5.9B | $980.2M | ||
| Q3 24 | $7.5B | $983.5M | ||
| Q2 24 | $5.9B | $945.8M | ||
| Q1 24 | $5.0B | $924.7M |
总资产AMGNNHC
| Q4 25 | $90.6B | $1.5B | ||
| Q3 25 | $90.1B | $1.6B | ||
| Q2 25 | $87.9B | $1.6B | ||
| Q1 25 | $89.4B | $1.5B | ||
| Q4 24 | $91.8B | $1.5B | ||
| Q3 24 | $90.9B | $1.6B | ||
| Q2 24 | $90.9B | $1.3B | ||
| Q1 24 | $93.0B | $1.3B |
负债/权益比AMGNNHC
| Q4 25 | 6.31× | 0.04× | ||
| Q3 25 | 5.67× | 0.07× | ||
| Q2 25 | 7.57× | 0.11× | ||
| Q1 25 | 9.24× | 0.13× | ||
| Q4 24 | 10.23× | 0.14× | ||
| Q3 24 | 8.02× | 0.15× | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $16.8M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $6.4M |
| 自由现金流率自由现金流/营收 | 9.7% | 1.7% |
| 资本支出强度资本支出/营收 | 6.5% | 2.7% |
| 现金转化率经营现金流/净利润 | 1.20× | 0.68× |
| 过去12个月自由现金流最近4个季度 | $8.1B | $148.6M |
8季度趋势，按日历期对齐
经营现金流AMGNNHC
| Q4 25 | $1.6B | $16.8M | ||
| Q3 25 | $4.7B | $66.2M | ||
| Q2 25 | $2.3B | $62.8M | ||
| Q1 25 | $1.4B | $39.3M | ||
| Q4 24 | $4.8B | $12.8M | ||
| Q3 24 | $3.6B | $34.2M | ||
| Q2 24 | $2.5B | $50.7M | ||
| Q1 24 | $689.0M | $9.6M |
自由现金流AMGNNHC
| Q4 25 | $961.0M | $6.4M | ||
| Q3 25 | $4.2B | $56.5M | ||
| Q2 25 | $1.9B | $52.6M | ||
| Q1 25 | $980.0M | $33.1M | ||
| Q4 24 | $4.4B | $4.6M | ||
| Q3 24 | $3.3B | $28.6M | ||
| Q2 24 | $2.2B | $42.8M | ||
| Q1 24 | $459.0M | $3.7M |
自由现金流率AMGNNHC
| Q4 25 | 9.7% | 1.7% | ||
| Q3 25 | 44.4% | 14.8% | ||
| Q2 25 | 20.8% | 14.0% | ||
| Q1 25 | 12.0% | 8.9% | ||
| Q4 24 | 48.4% | 1.3% | ||
| Q3 24 | 39.0% | 8.4% | ||
| Q2 24 | 26.5% | 14.2% | ||
| Q1 24 | 6.2% | 1.2% |
资本支出强度AMGNNHC
| Q4 25 | 6.5% | 2.7% | ||
| Q3 25 | 4.6% | 2.5% | ||
| Q2 25 | 4.0% | 2.7% | ||
| Q1 25 | 5.0% | 1.6% | ||
| Q4 24 | 4.1% | 2.2% | ||
| Q3 24 | 3.0% | 1.7% | ||
| Q2 24 | 2.8% | 2.6% | ||
| Q1 24 | 3.1% | 2.0% |
现金转化率AMGNNHC
| Q4 25 | 1.20× | 0.68× | ||
| Q3 25 | 1.46× | 1.69× | ||
| Q2 25 | 1.59× | 2.65× | ||
| Q1 25 | 0.80× | 1.22× | ||
| Q4 24 | 7.61× | 2.10× | ||
| Q3 24 | 1.26× | 0.80× | ||
| Q2 24 | 3.30× | 1.89× | ||
| Q1 24 | — | 0.37× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
NHC
| Inpatient Services Segment | $333.7M | 86% |
| Homecare Services Segment | $40.0M | 10% |
| Other | $11.2M | 3% |
| National | $1.6M | 0% |
